Short Interest in Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Grows By 20.9%

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) was the target of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 223,283 shares, an increase of 20.9% from the December 15th total of 184,642 shares. Based on an average daily volume of 230,112 shares, the short-interest ratio is currently 1.0 days. Currently, 3.8% of the shares of the stock are sold short. Currently, 3.8% of the shares of the stock are sold short. Based on an average daily volume of 230,112 shares, the short-interest ratio is currently 1.0 days.

Analyst Upgrades and Downgrades

SLRX has been the topic of a number of recent research reports. Wall Street Zen cut Salarius Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, January 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Salarius Pharmaceuticals in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Salarius Pharmaceuticals Trading Up 28.5%

NASDAQ:SLRX traded up $0.19 during trading hours on Monday, hitting $0.84. 5,993,436 shares of the stock traded hands, compared to its average volume of 619,609. The firm has a 50 day moving average price of $0.83 and a 200 day moving average price of $4.58. The firm has a market cap of $4.89 million, a price-to-earnings ratio of -0.02 and a beta of 0.33. Salarius Pharmaceuticals has a fifty-two week low of $0.51 and a fifty-two week high of $108.00.

Salarius Pharmaceuticals (NASDAQ:SLRX) last issued its quarterly earnings results on Friday, November 14th. The company reported ($1.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($33.60) by $31.79.

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc is a clinical?stage biopharmaceutical company focused on the discovery and development of novel small?molecule therapeutics that target epigenetic and post?translational modification pathways in cancer. The company’s lead candidate, seclidemstat (SP?2577), is designed to inhibit lysine?specific demethylase 1 (LSD1) and modulate the tumor microenvironment, with a primary focus on treating Ewing sarcoma, a rare and aggressive bone and soft tissue cancer affecting children and young adults.